According to a press release put out my Medibio, an evidence-based medical technology company located in Australia, Michael Phelps has been added to the organization’s Board of Directors.
Medibio most recently developed an objective test that will assist in the diagnosis of depression, chronic stress and other mental health disorders. The test is conducted via a heart monitor sending information to a computer which uses an algorithm to objectively quantify and characterize mental illness.
As an avid supporter and promoter of mental health, Phelps has been named to the Board after using the technology himself. He stated that the ease and objectivity associated with the test will make it useful for people everywhere because mental health is a difficult subject for people to discuss.
“I am honored to accept this appointment because I have personally experienced Medibio’s technology and believe it can help make a profound impact in diagnosing mental health and empowering people to seek the help and support they may need,” said Phelps. “In sports, there is so much focus on the physical aspects of performance, and athletes are analyzed from head to toe. But for many athletes, mental health has not been a topic of focus, and the data analysis aspect of it has been missing up until now.
Additionally, Phelps’ agent and Managing Director of Octagon’s Olympic and Action Sports division, Peter Carlisle, has been appointed to an alternate Board member position. Carlisle brings an extra level of understanding and experience in this field to the company.
“We sincerely welcome Michael and Peter to the board of Medibio and look forward to their contribution as the company continues to progress its unique mental illness diagnostic technology on many active pathways toward clinical and corporate validation. I am confident that this addition will be very warmly welcomed by all our shareholders,” Medibio Chairman Chris Indermaur said.
According to the Australian, Phelps’ prominence will help Medibio immensely. This will help the company push into the US mental health management market, not just that of Australia. The US market is valued at $200 billion, and Medibio wants to be a part of it.
Additionally, the article stated that Phelps reached out to Medibio, not the reverse, in order to be a part of something “transformative.” While discussing the topic and making people aware is important, Phelps said he wants to do more.
“I want to help others who are dealing with these challenges and make the process for them to take action easier and more understandable,” Phelps said.
About Medibio Limited
Medibio (ASX:MEB), is an evidence-based medical technology company that has developed an objective test to assist in the diagnosis and management of depression, chronic stress and other mental health disorders. Based on research conducted over 15 years at the University of Western Australia, this test utilizes patented (and patent pending) panel circadian, sleep and autonomic system biomarkers to objectively quantify and characterize mental illness. Medibio’s depression diagnostic is being validated in clinical studies undertaken by Johns Hopkins University School of Medicine and The University of Ottawa, among others. The clinical trials will support Medibio’s application to become the first FDA approved, objective, and evidence based approach to the diagnosis of mental health disorders. Medibio’s technology also provides an objective method for the assessment of stress and mental wellbeing that can be translated to the workplace stress/wellbeing market, wearable technology and App market.
My partner and I stumbled over here different page and
thought I might check things out. I like what I see so now
i am following you. Look forward to checking out your web
page again.